APOL1-mediated Kidney Disease
3 clinical trials · Condition
◉ Watch APOL1-mediated Kidney Disease
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants (NCT05324410) | Vertex Pharmaceuticals Incorporated | 2022-04-07 |
Track APOL1-mediated Kidney Disease automatically
Every clearance here is in the API, with alerts when new ones post.